The initial effects of the Inflation Reduction Act (IRA) are at hand, seen in negotiated prices of certain drugs and impending Medicare Part D changes in 2025.

Patients and advocates need to be prepared to understand and navigate these changes effectively, and manufacturers need to understand the patient voice to best communicate with and support patients taking their medicines considering this shifting system.

During this webinar, we explored and discussed:

  • The current burden on patients and their questions on how the IRA will impact access to medicines and provide guidance and recommendations on how to navigate these changes.
  • The IRA’s intended and unintended consequences, both in the short- and long-term, to prepare patients, advocates, and manufacturers to navigate the waters ahead and partner in our shared goal of a better lived experience for patients.
  • The Medicare Part D changes that will be implemented in 2025 and their impact to patient access.
  • The impact from the patient perspective of navigating issues around costs and access.
  • The advocacy perspective on the intended and unintended consequences of the IRA on patients.

Watch the recording of the webinar to learn how the provisions of the IRA will impact patients, help patients and advocacy organizations navigate its current and future impact, and reinforce the critical importance of the patient perspective to pharmaceutical manufacturers.

Question on the webinar or want to discuss how we can elevate your insights? Contact us.

Watch the recording

Presenters:

  • Patricia J. Goldsmith, C-Suite Officer and Strategic Business Advisor
  • Abigail Johnston, Lawyer and patient advocate
  • Leeann Lui, PharmD, Vice President, Pricing and Strategy, Lumanity
  • Holli Kawadler, PhD, Scientific Strategy & Content Lead, Lumanity